Shots: Endocyte to receive $24M/share in cash with total deal value of $2.1B. Novartis to get hold of all stocks with its RLT candidates Lu-PSMA-617 & Ac-PSMA-617 Lu-PSMA-617 is a […]readmore
Tags : Novartis
Shots: The P-II SUSTAIN study involves assessing of crizanlizumab 2.5/5 mg/kg vs PBO in 132 SCD patients with sickle cell-related pain crises P-II SUSTAIN study results: 2-4 event/yr. (40.5% vs […]readmore
Shots: The NDA and MAA Acceptance of Siponimod is based on P-III EXPAND study, assessing Siponimod vs PBO in adults with Secondary Progression Multiple Sclerosis (SPMS) evaluating its safety and […]readmore
Shots: Novartis out-licensed worldwide rights for its three drug candidates, including LYS228 & IID572 targeting carbapenem-resistant enterobacteriaceae (CRE) and MAK181 targeting Pseudomonas infections. Boston to pay an upfront, milestone and […]readmore
Shots: Novartis to get royalty-free worldwide, intellectual property rights for CBMG’s CAR-T related technology. CBMG to get a mark-up on the manufacturing cost. CBMG will take care of the manufacturing […]readmore
Shots: The survey enrolled 300 (US respondents) psoriasis patients are interested in additional benefits i.e. no. of years of proven efficacy and safety with no injection site reactions in addition […]readmore
Shots: Mylan reveals its undisclosed agreement signed on 30 July, 2018 for worldwide commercialization rights for Novartis’ global cystic fibrosis products,TOBI Podhaler and TOBI solution Company also revealed the reason […]readmore
Shots: In Oct, 2018 Pfizer appointed Dr. Albert Bourla as its new CEO, successor of Lan C. Read (7 Dec, 2010 – 31 Dec, 2018) In Feb, 2018 Novartis appointed […]readmore
Shots: Novartis sells a part of Sandoz US, which includes ~300 products that generated $0.6B in H1’18 This transaction includes development projects along with ~300 products to Aurobindo Pharma USA […]readmore
Shots: Novartis plans to increase its worldwide operating profit margins by making production efficient, in spite of dipping in prices for its drugs in the US The company aims to […]readmore